3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Endocrine
1
Conditions
Neoplasms
15
Endometrial Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Rectal Neoplasms
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Pancreatic Neoplasms
3
Melanoma
3
Colonic Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Osteosarcoma
2
Locally Advanced Rectal Cancer (LARC)
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Interventions
Doxorubicin
26
pembrolizumab
24
Radiotherapy
20
Cyclophosphamide
18
Magnetic Resonance Spectroscopy
17
Specimen Handling
14
Nivolumab
14
Gemcitabine
13
Ifosfamide
12
Surgical Procedures, Operative
11
Biopsy
11
Radiation
10
X-Rays
8
Temozolomide
8
Ipilimumab
8
pazopanib
7
fludarabine
7
cabozantinib
7
Irinotecan
7
tazemetostat
6
liposomal doxorubicin
6
Trabectedin
6
Surveys and Questionnaires
6
Phantoms, Imaging
6
Blood Specimen Collection
6
olaparib
5
eribulin
5
atezolizumab
5
anlotinib
5
Vincristine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
dostarlimab
×
1 year
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled